ECSP19000185A - Método para producir derivado de difenilmetano - Google Patents
Método para producir derivado de difenilmetanoInfo
- Publication number
- ECSP19000185A ECSP19000185A ECSENADI2019185A ECDI201900185A ECSP19000185A EC SP19000185 A ECSP19000185 A EC SP19000185A EC SENADI2019185 A ECSENADI2019185 A EC SENADI2019185A EC DI201900185 A ECDI201900185 A EC DI201900185A EC SP19000185 A ECSP19000185 A EC SP19000185A
- Authority
- EC
- Ecuador
- Prior art keywords
- diphenylmethane derivative
- synthesis route
- synthesis
- linear
- sglt
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 title abstract 2
- 102100037202 Sodium/myo-inositol cotransporter 2 Human genes 0.000 abstract 2
- 101710090560 Sodium/myo-inositol cotransporter 2 Proteins 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000001308 synthesis method Methods 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B51/00—Introduction of protecting groups or activating groups, not provided for in the preceding groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un método mejorado para producir un derivado de difenilmetano que es eficaz como un inhibidor del cotransportador de glucosa dependiente de sodio (SGLT), el método siendo realizado por medio de un método de síntesis convergente en el que cada grupo principal es sintetizado por separado y luego acoplado. Como tal, en comparación con un método de síntesis lineal descrito en documentos existentes, la vía de síntesis es compacta y el rendimiento puede aumentarse, y los factores de riesgo inherentes a la vía de síntesis lineal pueden reducirse. Además, la forma cristalina del compuesto producido de conformidad con el método tiene excelentes características fisicoquímicas y, por lo tanto, puede utilizarse eficazmente en campos tales como la fabricación de productos farmacéuticos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160075910 | 2016-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19000185A true ECSP19000185A (es) | 2019-01-31 |
Family
ID=60664449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI2019185A ECSP19000185A (es) | 2016-06-17 | 2019-01-04 | Método para producir derivado de difenilmetano |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10640496B2 (es) |
| EP (2) | EP3663292B1 (es) |
| JP (4) | JP6763978B2 (es) |
| KR (2) | KR102233229B1 (es) |
| CN (2) | CN113651803B (es) |
| AU (1) | AU2017285813B2 (es) |
| CA (2) | CA3026756C (es) |
| CL (1) | CL2018003645A1 (es) |
| CO (1) | CO2018014018A2 (es) |
| DK (2) | DK3663292T3 (es) |
| DO (1) | DOP2018000287A (es) |
| EC (1) | ECSP19000185A (es) |
| ES (2) | ES2891825T3 (es) |
| HR (1) | HRP20211670T8 (es) |
| HU (1) | HUE056428T2 (es) |
| MA (2) | MA50774B1 (es) |
| MX (2) | MX392177B (es) |
| MY (1) | MY203941A (es) |
| NZ (1) | NZ749398A (es) |
| PE (2) | PE20190467A1 (es) |
| PH (1) | PH12018550206A1 (es) |
| PL (2) | PL3663292T3 (es) |
| PT (2) | PT3473621T (es) |
| RS (1) | RS62550B1 (es) |
| SA (2) | SA518400666B1 (es) |
| SG (2) | SG11201811154QA (es) |
| SI (1) | SI3663292T1 (es) |
| TN (1) | TN2018000437A1 (es) |
| WO (1) | WO2017217792A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011054773A1 (de) | 2011-10-25 | 2013-04-25 | Vb Autobatterie Gmbh & Co. Kgaa | Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols |
| BR112021002523A2 (pt) | 2018-08-13 | 2021-05-04 | Daewoong Pharmaceutical Co., Ltd. | método para preparar um composto |
| CN112341416A (zh) * | 2019-08-09 | 2021-02-09 | 天津津艺医药科技发展有限责任公司 | 一种制备苯并含氧脂杂环衍生物的方法 |
| US12497390B2 (en) | 2020-02-27 | 2025-12-16 | Daewoong Pharmaceutical Co., Ltd. | Intermediate useful for synthesis of SGLT inhibitor and method for preparing SGLT inhibitor using same |
| CN112094253B (zh) * | 2020-09-10 | 2023-01-10 | 株式会社大熊制药 | 用于制备sglt抑制剂中间体的合成方法 |
| WO2022051980A1 (zh) * | 2020-09-10 | 2022-03-17 | 广东莱佛士制药技术有限公司 | 用于制备sglt抑制剂中间体的合成方法 |
| CN113200860B (zh) * | 2021-04-29 | 2024-07-30 | 爱斯特（成都）生物制药股份有限公司 | 一种sglt2抑制剂中间体的制备方法 |
| KR20230046784A (ko) * | 2021-09-30 | 2023-04-06 | 주식회사 대웅제약 | 이나보글리플로진을 포함하는 약학 조성물 |
| CN113801010A (zh) * | 2021-11-18 | 2021-12-17 | 山东诚创蓝海医药科技有限公司 | 一种5-溴-2-氯苯甲酸的制备方法 |
| CN113912487B (zh) * | 2021-11-23 | 2024-05-28 | 山东研峰新材料科技有限公司 | 一种2,5-双卤代苯甲酸的合成方法 |
| KR102994906B1 (ko) * | 2022-01-14 | 2026-07-24 | 주식회사 대웅제약 | Sglt 저해제의 합성에 유용한 중간체의 제조 방법 |
| KR20240044194A (ko) * | 2022-09-28 | 2024-04-04 | 주식회사 대웅제약 | 이나보글리플로진의 신규한 공결정 |
| KR20240044190A (ko) | 2022-09-28 | 2024-04-04 | 주식회사 대웅제약 | 이나보글리플로진의 신규한 결정형 및 이의 제조방법 |
| WO2024072079A1 (ko) | 2022-09-29 | 2024-04-04 | 주식회사 대웅제약 | 이나보글리플로진을 포함하는 심혈관 노화 질환 예방 또는 치료용 약학 조성물 |
| US20260130933A1 (en) | 2022-10-05 | 2026-05-14 | Daewoong Pharmaceutical Co., Ltd. | Pharmaceutical composition for prevention or treatment of nephropathy and/or diabetes mellitus, comprising enavogliflozin |
| AU2023412900A1 (en) | 2022-12-21 | 2025-06-12 | Daewoong Therapeutics Inc. | Eye drop-type pharmaceutical composition containing envogliflozin |
| KR20240107660A (ko) * | 2022-12-30 | 2024-07-09 | 주식회사 대웅제약 | 이나보글리플로진 및 메트포르민을 포함하는 약학 조성물 |
| CN122438688A (zh) | 2023-12-27 | 2026-07-21 | 株式会社大熊制药 | 包含依那格列净作为活性成分的用于预防或治疗斑秃的药物组合物 |
| KR102837941B1 (ko) * | 2024-11-13 | 2025-07-25 | 대웅바이오(주) | Inline quenching 공정을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법 |
| KR102837948B1 (ko) * | 2024-11-13 | 2025-07-25 | 대웅바이오(주) | 분배 투입법을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법 |
| KR102853437B1 (ko) * | 2024-11-13 | 2025-09-04 | 대웅바이오(주) | 연속반응 공정을 이용한 이나보글리플로진 합성방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4966907A (en) * | 1988-08-12 | 1990-10-30 | Merck & Co., Inc. | 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis |
| CN104109155A (zh) * | 2003-08-01 | 2014-10-22 | 田边三菱制药株式会社 | 新颖化合物 |
| UA107175C2 (uk) | 2007-07-26 | 2014-12-10 | Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти | |
| BRPI0916395A2 (pt) | 2008-07-30 | 2016-02-16 | Ferrer Int | compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| WO2012041898A1 (en) * | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes |
| JP5876570B2 (ja) * | 2011-06-01 | 2016-03-02 | グリーン・クロス・コーポレイションＧｒｅｅｎ Ｃｒｏｓｓ Ｃｏｒｐ． | Ｓｇｌｔ２阻害剤としての新規のジフェニルメタン誘導体 |
| US9340521B2 (en) | 2013-03-18 | 2016-05-17 | Green Cross Corporation | Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives |
| FR3017868A1 (fr) | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2017
- 2017-06-15 MY MYPI2018002498A patent/MY203941A/en unknown
- 2017-06-15 WO PCT/KR2017/006271 patent/WO2017217792A1/ko not_active Ceased
- 2017-06-15 ES ES17813615T patent/ES2891825T3/es active Active
- 2017-06-15 MX MX2021008988A patent/MX392177B/es unknown
- 2017-06-15 KR KR1020170075799A patent/KR102233229B1/ko active Active
- 2017-06-15 EP EP20152959.1A patent/EP3663292B1/en active Active
- 2017-06-15 ES ES20152959T patent/ES2898336T3/es active Active
- 2017-06-15 DK DK20152959.1T patent/DK3663292T3/da active
- 2017-06-15 MA MA50774A patent/MA50774B1/fr unknown
- 2017-06-15 RS RS20211297A patent/RS62550B1/sr unknown
- 2017-06-15 PE PE2018003162A patent/PE20190467A1/es unknown
- 2017-06-15 CN CN202110860586.9A patent/CN113651803B/zh active Active
- 2017-06-15 NZ NZ749398A patent/NZ749398A/en unknown
- 2017-06-15 CN CN201780036968.1A patent/CN109311861B/zh active Active
- 2017-06-15 JP JP2018565754A patent/JP6763978B2/ja active Active
- 2017-06-15 SG SG11201811154QA patent/SG11201811154QA/en unknown
- 2017-06-15 PT PT17813615T patent/PT3473621T/pt unknown
- 2017-06-15 CA CA3026756A patent/CA3026756C/en active Active
- 2017-06-15 PL PL20152959T patent/PL3663292T3/pl unknown
- 2017-06-15 EP EP17813615.6A patent/EP3473621B1/en active Active
- 2017-06-15 MA MA44545A patent/MA44545B2/fr unknown
- 2017-06-15 AU AU2017285813A patent/AU2017285813B2/en active Active
- 2017-06-15 MX MX2018015647A patent/MX385640B/es unknown
- 2017-06-15 PL PL17813615T patent/PL3473621T3/pl unknown
- 2017-06-15 DK DK17813615.6T patent/DK3473621T3/da active
- 2017-06-15 US US16/310,005 patent/US10640496B2/en active Active
- 2017-06-15 CA CA3081033A patent/CA3081033C/en active Active
- 2017-06-15 PE PE2023002240A patent/PE20240590A1/es unknown
- 2017-06-15 TN TNP/2018/000437A patent/TN2018000437A1/en unknown
- 2017-06-15 PT PT201529591T patent/PT3663292T/pt unknown
- 2017-06-15 SI SI201730944T patent/SI3663292T1/sl unknown
- 2017-06-15 HU HUE20152959A patent/HUE056428T2/hu unknown
- 2017-06-15 HR HRP20211670TT patent/HRP20211670T8/hr unknown
- 2017-06-15 SG SG10201911782RA patent/SG10201911782RA/en unknown
-
2018
- 2018-12-15 SA SA518400666A patent/SA518400666B1/ar unknown
- 2018-12-15 SA SA521422474A patent/SA521422474B1/ar unknown
- 2018-12-17 CL CL2018003645A patent/CL2018003645A1/es unknown
- 2018-12-17 DO DO2018000287A patent/DOP2018000287A/es unknown
- 2018-12-17 PH PH12018550206A patent/PH12018550206A1/en unknown
- 2018-12-21 CO CONC2018/0014018A patent/CO2018014018A2/es unknown
-
2019
- 2019-01-04 EC ECSENADI2019185A patent/ECSP19000185A/es unknown
- 2019-08-30 US US16/557,180 patent/US10889574B2/en active Active
-
2020
- 2020-04-06 JP JP2020068458A patent/JP7352509B2/ja active Active
-
2021
- 2021-03-22 KR KR1020210036824A patent/KR102379584B1/ko active Active
- 2021-06-21 JP JP2021102648A patent/JP7669206B2/ja active Active
-
2023
- 2023-07-06 JP JP2023111632A patent/JP7773506B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018015647A (es) | Metodo para producir derivado de difenilmetano. | |
| MX2021005598A (es) | Sintesis mejorada del intermedio clave del compuesto inhibidor de g12c de kras. | |
| CL2019002297A1 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos. | |
| MX2014012268A (es) | Proceso para la preparacion de inhibidores del cotransportador de glucosa dependiente de bencilbencen sodio 2 (sglt2). | |
| MX2018014162A (es) | Procesos para preparar oligomeros de morfolino fosforodiamidato. | |
| NZ736108A (en) | Novel rig-i ligands and methods for producing them | |
| CO2018013834A2 (es) | Procesos para preparar oligómeros de morfolino fosforodiamidato | |
| MX2016013557A (es) | Produccion de 4-metil-tetrahidropiranos 2-sustituidos a partir de materiales de partida con contenido de 2-alquil-4,4-dimetil-1,3-di oxanos. | |
| EA201500648A1 (ru) | (6r,10r)-6,10,14-триметилпентадекан-2-он, получаемый из 6,10-диметилундец-5-ен-2-она или 6,10-диметилундека-5,9-диен-2-она | |
| UA116825C2 (uk) | Морфологічні форми гексадецилоксипропілових складних ефірів фосфонової кислоти і способи їх синтезу | |
| MX2017011407A (es) | Metodo para producir esteres de tetrahidropiranilo. | |
| GB201319839D0 (en) | Synthesis and use of glycoside derivatives of propofol | |
| MX2017001459A (es) | Sintesis de fosforamidatos. | |
| CO2018013831A2 (es) | Procesos para preparar oligómeros de morfolino fosforodiamidato | |
| NZ720106A (en) | A process for the preparation of regadenoson | |
| BR112013032081A2 (pt) | sistema de distribuição extrudado | |
| CO2021001857A2 (es) | Preparación de intermedio útil para la síntesis de inhibidor de sglt | |
| MX2019006959A (es) | Procesos para la preparacion de compuestos de pirimidinilciclopentano. | |
| MX2022001845A (es) | Metodo para eliminar del vidrio metales perturbadores tales como hierro. | |
| CL2022001806A1 (es) | Método para producir derivado de difenilmetano. | |
| AR102166A1 (es) | Método de fabricación de un péptido derivado de tapsigargina | |
| MX2016008281A (es) | Procedimientos mejorados para producir propilenglicol. | |
| MX2014014512A (es) | Proceso para producir 4-ciclohexil-2-metil-2-butanol. | |
| EA201791098A1 (ru) | Способ синтеза производных бензазепина | |
| BR112023000227A2 (pt) | Processo para preparação de dismina |